Sr Executive-Quality Assurance

As a global integrated pharmaceutical company, Jubilant Pharma Limited offers a diverse range of products and services to customers worldwide. The business is structured into two key segments: Specialty Pharmaceuticals and Generics & APIs. Specialty Pharmaceuticals includes Radiopharmaceuticals, Contract Manufacturing of Sterile Injectable, Non-sterile & Allergy Therapy Products. Generics & APIs includes Solid Dosage Formulations & Active Pharmaceutical Ingredients. Jubilant Generics (JGL), a wholly-owned subsidiary, operates in India with Research & Development units in Noida and Mysore. JGL has manufacturing facilities in Mysore, Karnataka and Roorkee, Uttarakhand, focusing on APIs and Dosage manufacturing respectively. The Mysore manufacturing site, spread over 69 acres, is USFDA approved and produces APIs for global sales, with a portfolio concentrating on Lifestyle driven Therapeutic Areas (CVS, CNS). The Roorkee facility is a state-of-the-art site approved by multiple regulatory bodies including USFDA, Japan PMDA, UK MHRA, TGA, WHO, and Brazil ANVISA. Both manufacturing units are supported by around 500 research and development professionals based at Noida and Mysore. The R&D team works on developing new products in API, Solid Dosage Formulations, Sterile Injectable, Semi-Solids Ointments, Creams, and Liquids. The company conducts BA/BE studies in-house at an 80 Bed facility with global regulatory accreditations. JGL's Regulatory Affairs & IPR professionals manage a unique portfolio of patents and product filings in regulatory and non-regulatory markets. Jubilant Pharma's revenue has shown a consistent increase, reaching INR 53,240 Million during the Financial Year 2018-19 compared to INR 39,950 Million in the Financial Year 2017-18. For more information about the organization, please visit www.jubilantpharma.com.,